ClinicalTrials.gg
TerminatedNCT05818150MOTIONUpdated Nov 20, 2026

GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

An interventional study of Embosphere Microspheres and Corticosteroid injection in Knee Osteoarthritis, sponsored by Merit Medical Systems, Inc.. Terminated at 17 sites in 4 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Merit Medical Systems, Inc. · Not applicable, Interventional, and Treatment

How we know · 4 judgments

Why this study was terminated
Sponsor decision to terminate the study.
Updated Nov 20, 2026Now TerminatedNo longer in Australia and United Kingdom+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
414th of 691
52 · median 72
Started
2024
with 30 others
No phase
376 of 796
54 open now
Registered
679th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 414th largest by enrollment of the 691 interventional ones that give a count, is one of 31 that started in 2024, is one of 376 with no phase, and was the 679th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.

Read the detailed description

This study is an IDE study. It is an RCT comparing GAE to steroid injection in the knee to treat knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • genicular artery embolization
  • GAE
  • knee embolization
  • knee OA
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Provides written

Age ≥21 years

Mild to severe knee pain, defined as a WOMAC Pain score of ≥8 out of 20 (in the target knee)

Pain to conservative therapies for at least 90 days prior to enrollment/randomization.

Kellgren-Lawrence grade 1, 2, 3 or 4

Key Exclusion Criteria:

Planned major surgical or endovascular procedures ≤ 30 days after the index procedure.

Advanced atherosclerosis

Known history of rheumatoid or infectious arthritis.

Prior knee replacement surgery of the target knee.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Genicular artery embolization with Embosphere Microspheres

    Device: Embosphere Microspheres Embolic Agent: Embosphere Microspheres

    Device: Embosphere Microspheres

  • Active comparator
    Corticosteroid Injection of the knee

    Drug: Corticosteroid injection

    Drug: Corticosteroid injection

Interventions

  • DeviceEmbosphere Microspheres

    Embolic Agent: Embosphere Microspheres

    Also known as: Genicular artery embolization

  • DrugCorticosteroid injection

    Corticosteroid injection

    Also known as: Triamcinolone or methylprednisolone

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint

    Clinical Success defined as ≥50% improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale from baseline to 6 months without the need for additional intervention.

    Time frame: 6 months

  2. Primary Safety Endpoint

    Freedom from treatment-related safety events through 6 months (180 days) following the index procedure.

    Time frame: 6 months

Secondary outcomes

  1. Subjects achieving Clinical Success

    Number of subjects achieving Clinical Success

    Time frame: 3, 12, and 24 months

  2. Numerical rating scale (NRS)

    Pain score assessed using numerical rating scale (NRS)

    Time frame: baseline, 3, 6, 12 and 24 months

07

Study locations

17 sites
08

References and documents

Publications

  • Bent C, McAsey CJ, Bagla S. Multicenter, PrOspective, Randomized, Controlled Trial Comparing GenIcular Artery EmbOlization Using Embosphere Microspheres to Corticosteroid iNjections for the Treatment of Symptomatic Knee Osteoarthritis: MOTION Study Protocol Summary. Cardiovasc Intervent Radiol. 2025 Apr;48(4):551-558. doi: 10.1007/s00270-025-03994-z. Epub 2025 Mar 6. PubMed 40050421 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in May 2026, 28 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Apr 2026 → May 2026 and completion Oct 2027 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2023
First posted
Apr 18, 2023
StartActual
Jan 16, 2024
Primary completionActual
May 28, 2026was Apr 2026
CompletionActual
May 28, 2026was Oct 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Sponsor decision to terminate the study.
changed Nov 20, 2026
Sites
10 sites removed; no longer in Australia and United Kingdom
Show 10 removed
  • Memorial Care Long Beach Medical Center · Long Beach, United States
  • MedStar Washington Hospital Center · Washington D.C., United States
  • Biotech Clinical Research/ Georgia Vascular Institute · College Park, United States
  • Massachusetts General Hospital · Boston, United States
  • Rutgers Health · Newark, United States
  • Weill Cornell Medicine · New York, United States
  • Liverpool Hospital · Liverpool, Australia
  • CHUM - Centre hospitalier de l'Université de Montréal · Montreal, Canada
  • University Hospitals Dorset · Bournemouth, United Kingdom
  • Grange University Hospital · Cwmbran, United Kingdom
Nov 20, 2026
Primary completion
Apr 2026→May 28, 2026 (actual)
Nov 20, 2026
Study completion
Oct 2027→May 28, 2026 (actual)
Nov 20, 2026
Enrollment
264 (estimated)→52 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Active, not recruiting→Terminated
    Why stopped Sponsor decision to terminate the study.
    10 sites removed; no longer in Australia and United Kingdom
    Show 10 removed
    • Memorial Care Long Beach Medical Center · Long Beach, United States
    • MedStar Washington Hospital Center · Washington D.C., United States
    • Biotech Clinical Research/ Georgia Vascular Institute · College Park, United States
    • Massachusetts General Hospital · Boston, United States
    • Rutgers Health · Newark, United States
    • Weill Cornell Medicine · New York, United States
    • Liverpool Hospital · Liverpool, Australia
    • CHUM - Centre hospitalier de l'Université de Montréal · Montreal, Canada
    • University Hospitals Dorset · Bournemouth, United Kingdom
    • Grange University Hospital · Cwmbran, United Kingdom
    Primary completion Apr 2026→May 28, 2026 (now actual)
    Study completion Oct 2027→May 28, 2026 (now actual)
    Enrollment 264 (estimated)→52 (actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05818150
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Jan 16, 2024
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Nov 20, 2026

Study contacts

Sandeep Bagla, MD
principal investigator · Prostate Centers, USA
Craig J McAsey, MD
principal investigator · Anderson Orthopedic Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion